Novel dual and triple agonists targeting GLP-1, GIP, Glucagon, and GDF15 for type 2 diabetes and obesity management
1. 系统已在2025-11-19 11:32:32对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
J Zhang, S Sanan, M Csanalosi, C Zheng…
…, 2025
academic.oup.com
The rising global incidence of type 2 diabetes mellitus (T2DM) and obesity underscores a critical public health challenge, with obesity serving as a primary contributor to insulin resistance. Current treatment modalities, including SGLT2 inhibitors and GLP-1 receptor agonists, have shown efficacy in glycemic control and weight management but remain insufficient for all patients. This review focuses on novel dual and triple agonists targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) …
